Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul 27:9:931595.
doi: 10.3389/fcvm.2022.931595. eCollection 2022.

Emergently Alteration of Procedural Strategy During Transcatheter Aortic Valve Replacement to Prevent Coronary Occlusion: A Case Report

Affiliations
Case Reports

Emergently Alteration of Procedural Strategy During Transcatheter Aortic Valve Replacement to Prevent Coronary Occlusion: A Case Report

Hanyi Dai et al. Front Cardiovasc Med. .

Abstract

Background: Coronary occlusion is an uncommon but fatal complication of transcatheter aortic valve replacement (TAVR) with a poor prognosis.

Case presentation: A patient with symptomatic severe bicuspid aortic valve stenosis was admitted to a high-volume center specializing in transfemoral TAVR with self-expanding valves. No anatomical risk factors of coronary occlusion were identified on pre-procedural computed tomography analysis. The patient was scheduled for a transfemoral TAVR with a self-expanding valve. Balloon pre-dilatation prior to prosthesis implantation was routinely used for assessing the supra-annular structure and assessing the risk of coronary occlusion. Immediately after the tubular balloon inflation, fluoroscopy revealed that the right coronary artery was not visible, and the flow in the left coronary artery was reduced. The patient would be at high-risk of coronary occlusion if a long stent self-expanding valve was implanted. Therefore, our heart team decided to suspend the ongoing procedure. A transapical TAVR with a 23 mm J-valve was performed 3 days later. The prosthesis was deployed at a proper position without blocking the coronary ostia and the final fluoroscopy showed normal flow in bilateral coronary arteries with the same filling as preoperatively.

Discussion: Our successful case highlights the importance of a comprehensive assessment of coronary risk and a thorough understanding of the TAVR procedure for the heart team. A short-stent prosthesis is feasible for patients at high risk of coronary occlusion. Most importantly TAVR should be called off even if the catheter has been introduced when an extremely high risk of coronary obstruction is identified during the procedure and no solution can be found.

Keywords: aortic valve stenosis; emergent; pre-dilatation; procedural strategy; transcatheter aortic valve replacement.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Pre-procedural computed tomography assessment of aortic root. (A) Annular perimeter: 73.1 mm and annular area: 414.1 mm2. (B) Left-, right- and non-sinuses of Valsalva dimensions: 31.6 mm * 30.7 mm * 30.7 mm. (C) Average sinotubular junction diameter: 27.6 mm. (D,E) The height of coronary arteries: 11 mm (left) and 14.1 mm (right). (F) The distance from the edge of the calcified nodule to right coronary ostium: 23 mm.
FIGURE 2
FIGURE 2
Intraoperative fluoroscopy. (A) Fluoroscopy showed bilateral patent coronary arteries before balloon pre-dilatation. (B) The right coronary artery was invisible and reduced blood flow in the left coronary artery during the balloon dilatation. (C) Fluoroscopy showed the patency of bilateral coronary arteries after J-valve deployment.
FIGURE 3
FIGURE 3
The J-Valve system design. The J-Valve aortic system consists of a self-expanding nitinol stent surrounded by three U-shaped anchor rings, with porcine aortic valve leaflets sutured inside. This draft was provided by the company JieCheng Medical Technology Co., Ltd., Suzhou, China.

Similar articles

References

    1. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, III, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. (2021) 77:450–500. 10.1016/j.jacc.2020.11.035 - DOI - PubMed
    1. Ribeiro HB, Nombela-Franco L, Urena M, Mok M, Pasian S, Doyle D, et al. Coronary obstruction following transcatheter aortic valve implantation: a systematic review. JACC Cardiovasc Interv. (2013) 6:452–61. 10.1016/j.jcin.2012.11.014 - DOI - PubMed
    1. Ribeiro HB, Webb JG, Makkar RR, Cohen MG, Kapadia SR, Kodali S, et al. Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry. J Am Coll Cardiol. (2013) 62:1552–62. 10.1016/j.jacc.2013.07.040 - DOI - PubMed
    1. Zhou D, Yidilisi A, Fan J, Zhang Y, Dai H, Zhu G, et al. Three-year outcomes of transcatheter aortic valve implantation for bicuspid versus tricuspid aortic stenosis. EuroIntervention. (2022) 18:193–202. 10.4244/EIJ-D-21-00734 - DOI - PMC - PubMed
    1. Chen M, Michel J, Kasel AM. Application of balloon-expandable transcatheter heart valve in bicuspid aortic valve. JACC Asia. (2021) 1:147–61. 10.1016/j.jacasi.2021.07.012 - DOI - PMC - PubMed

Publication types

LinkOut - more resources